Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1992 Jul;76(3):452–459.

Differential effects of a murine and chimeric mouse/human anti-interleukin-2 receptor antibody on human T-cell proliferation.

B Rose 1, A Gillespie 1, D Wunderlich 1, K Kelley 1, J Dzuiba 1, D Shedd 1, K Cahill 1, B Zerler 1
PMCID: PMC1421677  PMID: 1526654

Abstract

The preference for interleukin-2 receptor (IL-2R) expression on activated, compared with resting T lymphocytes makes the IL-2R a promising target for selective immunosuppressive therapy. To increase the potential therapeutic effectiveness of anti-IL-2R monoclonals, a chimeric mouse/human variant was constructed from Ig genes isolated from a murine anti-human IL-2R hybridoma cell line, designated AHT54. AHT54 binds to the same or spatially related epitope as IL-2 on the p55 protein that constitutes the low- and high-affinity forms of IL-2R. Although the murine and chimeric AHT54 antibodies inhibited cell-surface binding of IL-2 to the same extent, the chimeric antibodies containing a human IgG1 constant region had substantially more anti-proliferative activity than their murine IgG1 counterparts. Our results indicated that the human constant region of the chimeric antibodies interacted more efficiently than the murine constant region with effector components present in peripheral blood mononuclear cells (PBMC).

Full text

PDF
452

Images in this article

456Figure 3
on p.456

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cantarovich D., Le Mauff B., Hourmant M., Peyronnet P., Jacques Y., Boeffard F., Hirn M., Soulillou J. P. Prophylactic use of a monoclonal antibody (33B3.1) directed against interleukin 2 receptor following human renal transplantation. Am J Kidney Dis. 1988 Feb;11(2):101–106. doi: 10.1016/s0272-6386(88)80189-6. [DOI] [PubMed] [Google Scholar]
  2. Cantrell D. A., Smith K. A. The interleukin-2 T-cell system: a new cell growth model. Science. 1984 Jun 22;224(4655):1312–1316. doi: 10.1126/science.6427923. [DOI] [PubMed] [Google Scholar]
  3. Dyer M. J., Hale G., Hayhoe F. G., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989 May 1;73(6):1431–1439. [PubMed] [Google Scholar]
  4. Ellison J. W., Berson B. J., Hood L. E. The nucleotide sequence of a human immunoglobulin C gamma1 gene. Nucleic Acids Res. 1982 Jul 10;10(13):4071–4079. doi: 10.1093/nar/10.13.4071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Herlyn D., Herlyn M., Steplewski Z., Koprowski H. Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol. 1985 Apr 15;92(1):105–114. doi: 10.1016/0008-8749(85)90068-1. [DOI] [PubMed] [Google Scholar]
  6. Hieter P. A., Max E. E., Seidman J. G., Maizel J. V., Jr, Leder P. Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments. Cell. 1980 Nov;22(1 Pt 1):197–207. doi: 10.1016/0092-8674(80)90168-3. [DOI] [PubMed] [Google Scholar]
  7. Honjo T., Obata M., Yamawaki-Katoaka Y., Kataoka T., Kawakami T., Takahashi N., Mano Y. Cloning and complete nucleotide sequence of mouse immunoglobulin gamma 1 chain gene. Cell. 1979 Oct;18(2):559–568. doi: 10.1016/0092-8674(79)90072-2. [DOI] [PubMed] [Google Scholar]
  8. Junghans R. P., Waldmann T. A., Landolfi N. F., Avdalovic N. M., Schneider W. P., Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990 Mar 1;50(5):1495–1502. [PubMed] [Google Scholar]
  9. Khazaeli M. B., Saleh M. N., Wheeler R. H., Huster W. J., Holden H., Carrano R., LoBuglio A. F. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst. 1988 Aug 17;80(12):937–942. doi: 10.1093/jnci/80.12.937. [DOI] [PubMed] [Google Scholar]
  10. Kirkman R. L., Shapiro M. E., Carpenter C. B., McKay D. B., Milford E. L., Ramos E. L., Tilney N. L., Waldmann T. A., Zimmerman C. E., Strom T. B. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation. 1991 Jan;51(1):107–113. doi: 10.1097/00007890-199101000-00016. [DOI] [PubMed] [Google Scholar]
  11. Kirkman R. L., Shapiro M. E., Carpenter C. B., Milford E. L., Ramos E. L., Tilney N. L., Waldmann T. A., Zimmerman C. E., Strom T. B. Early experience with anti-Tac in clinical renal transplantation. Transplant Proc. 1989 Feb;21(1 Pt 2):1766–1768. [PubMed] [Google Scholar]
  12. Kyle V., Coughlan R. J., Tighe H., Waldmann H., Hazleman B. L. Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis. Ann Rheum Dis. 1989 May;48(5):428–429. doi: 10.1136/ard.48.5.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Leonard W. J., Depper J. M., Uchiyama T., Smith K. A., Waldmann T. A., Greene W. C. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature. 1982 Nov 18;300(5889):267–269. doi: 10.1038/300267a0. [DOI] [PubMed] [Google Scholar]
  14. Liu A. Y., Robinson R. R., Hellström K. E., Murray E. D., Jr, Chang C. P., Hellström I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A. 1987 May;84(10):3439–3443. doi: 10.1073/pnas.84.10.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Liu A. Y., Robinson R. R., Murray E. D., Jr, Ledbetter J. A., Hellström I., Hellström K. E. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol. 1987 Nov 15;139(10):3521–3526. [PubMed] [Google Scholar]
  16. Lubeck M. D., Steplewski Z., Baglia F., Klein M. H., Dorrington K. J., Koprowski H. The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J Immunol. 1985 Aug;135(2):1299–1304. [PubMed] [Google Scholar]
  17. Meeker T. C., Lowder J., Maloney D. G., Miller R. A., Thielemans K., Warnke R., Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985 Jun;65(6):1349–1363. [PubMed] [Google Scholar]
  18. Morrison S. L. Transfectomas provide novel chimeric antibodies. Science. 1985 Sep 20;229(4719):1202–1207. doi: 10.1126/science.3929380. [DOI] [PubMed] [Google Scholar]
  19. Mulligan R. C., Berg P. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2072–2076. doi: 10.1073/pnas.78.4.2072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Osawa H., Diamantstein T. Studies on the formation of high-affinity IL-2 binding sites of an IL-2 receptor p55 + p75 heterodimeric complex: functional importance of a determinant on the p55 subunit defined by a monoclonal antibody AHT-107. Immunol Lett. 1989 Feb;20(3):205–212. doi: 10.1016/0165-2478(89)90081-3. [DOI] [PubMed] [Google Scholar]
  21. Pirofski L., Casadevall A., Rodriguez L., Zuckier L. S., Scharff M. D. Current state of the hybridoma technology. J Clin Immunol. 1990 Nov;10(6 Suppl):5S–14S. doi: 10.1007/BF00918686. [DOI] [PubMed] [Google Scholar]
  22. Rose B., Gillespie A., Wunderlich D., Barbosa J. A., Cahill K., Dzuiba J., Shedd D., Zerler B. A chimeric mouse/human anti-IL-2 receptor antibody with enhanced biological activities. Mol Immunol. 1992 Jan;29(1):131–144. doi: 10.1016/0161-5890(92)90164-s. [DOI] [PubMed] [Google Scholar]
  23. Smith K. A., Favata M. F., Oroszlan S. Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. J Immunol. 1983 Oct;131(4):1808–1815. [PubMed] [Google Scholar]
  24. Smith K. A. The interleukin 2 receptor. Adv Immunol. 1988;42:165–179. doi: 10.1016/s0065-2776(08)60844-5. [DOI] [PubMed] [Google Scholar]
  25. Soulillou J. P., Cantarovich D., Le Mauff B., Giral M., Robillard N., Hourmant M., Hirn M., Jacques Y. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med. 1990 Apr 26;322(17):1175–1182. doi: 10.1056/NEJM199004263221702. [DOI] [PubMed] [Google Scholar]
  26. Southern P. J., Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet. 1982;1(4):327–341. [PubMed] [Google Scholar]
  27. Thistlethwaite J. R., Jr, Stuart J. K., Mayes J. T., Gaber A. O., Woodle S., Buckingham M. R., Stuart F. P. Complications and monitoring of OKT3 therapy. Am J Kidney Dis. 1988 Feb;11(2):112–119. doi: 10.1016/s0272-6386(88)80192-6. [DOI] [PubMed] [Google Scholar]
  28. Waldmann T. A., Goldman C. K., Bongiovanni K. F., Sharrow S. O., Davey M. P., Cease K. B., Greenberg S. J., Longo D. L. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood. 1988 Nov;72(5):1805–1816. [PubMed] [Google Scholar]
  29. Wijdenes J., Beliard R., Muot S., Herve P., Peters A. A semi-pharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study. Dev Biol Stand. 1990;71:103–111. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES